A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET

Murali Chintagumpala, Tim Hassall, Shawna Palmer, David Ashley, Dana Wallace, Kimberly Kasow, Thomas E. Merchant, Matthew J. Krasin, Robert Dauser, Frederick Boop, Robert Krance, Shiao Woo, Robyn Cheuk, Ching Lau, Richard Gilbertson, Amar Gajjar

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

We undertook this study to estimate the event-free survival (EFS) of patients with newly diagnosed supratento-rial primitive neuroectodermal tumor (SPNET) treated with risk-adapted craniospinal irradiation (CSI) with additional radiation to the primary tumor site and subsequent high-dose chemotherapy supported by stem cell rescue. Between 1996 and 2003, 16 patients with SPNET were enrolled. High-risk (HR) disease was differentiated from average-risk (AR) disease by the presence of residual tumor (M0 and tumor size > 1.5 cm2) or disseminated disease in the neuraxis (M1-M 3). Patients received risk-adapted CSI: those with AR disease received 23.4 Gy; those with HR disease, 36-39.6 Gy. The tumor bed received a total of 55.8 Gy. Subsequently, all patients received four cycles of high-dose cyclophosphamide, cisplatin, and vincristine with stem cell support. The median age at diagnosis was 7.9 years; eight patients were female. Seven patients had pineal PNET. Twelve patients are alive at a median follow-up of 5.4 years. The 5-year EFS and overall survival (OS) estimates for all patients were 68% ± 14% and 73% ± 13%. The 5-year EFS and OS estimates were 75% ± 17% and 88% ± 13%, respectively, for the eight patients with AR disease and 60% ± 19% and 58% ± 19%, respectively, for the eight with HR disease. No deaths were due to toxicity. High-dose cyclophosphamide- based chemotherapy with stem cell support after risk-adapted CSI results in excellent EFS estimates for patients with newly diagnosed AR SPNET. Further, this chemotherapy allows for a reduction in the dose of CSI used to treat AR SPNET without compromising EFS.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalNeuro-oncology
Volume11
Issue number1
DOIs
StatePublished - Feb 1 2009

Fingerprint

Primitive Neuroectodermal Tumors
Radiotherapy
Drug Therapy
Craniospinal Irradiation
Disease-Free Survival
Stem Cells
Cyclophosphamide
Neoplasms
Survival
Residual Neoplasm
Vincristine
Cisplatin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Chintagumpala, M., Hassall, T., Palmer, S., Ashley, D., Wallace, D., Kasow, K., ... Gajjar, A. (2009). A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro-oncology, 11(1), 33-40. https://doi.org/10.1215/15228517-2008-079

A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. / Chintagumpala, Murali; Hassall, Tim; Palmer, Shawna; Ashley, David; Wallace, Dana; Kasow, Kimberly; Merchant, Thomas E.; Krasin, Matthew J.; Dauser, Robert; Boop, Frederick; Krance, Robert; Woo, Shiao; Cheuk, Robyn; Lau, Ching; Gilbertson, Richard; Gajjar, Amar.

In: Neuro-oncology, Vol. 11, No. 1, 01.02.2009, p. 33-40.

Research output: Contribution to journalArticle

Chintagumpala, M, Hassall, T, Palmer, S, Ashley, D, Wallace, D, Kasow, K, Merchant, TE, Krasin, MJ, Dauser, R, Boop, F, Krance, R, Woo, S, Cheuk, R, Lau, C, Gilbertson, R & Gajjar, A 2009, 'A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET', Neuro-oncology, vol. 11, no. 1, pp. 33-40. https://doi.org/10.1215/15228517-2008-079
Chintagumpala M, Hassall T, Palmer S, Ashley D, Wallace D, Kasow K et al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro-oncology. 2009 Feb 1;11(1):33-40. https://doi.org/10.1215/15228517-2008-079
Chintagumpala, Murali ; Hassall, Tim ; Palmer, Shawna ; Ashley, David ; Wallace, Dana ; Kasow, Kimberly ; Merchant, Thomas E. ; Krasin, Matthew J. ; Dauser, Robert ; Boop, Frederick ; Krance, Robert ; Woo, Shiao ; Cheuk, Robyn ; Lau, Ching ; Gilbertson, Richard ; Gajjar, Amar. / A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. In: Neuro-oncology. 2009 ; Vol. 11, No. 1. pp. 33-40.
@article{31f95a074c264695b7fd1ad1bc02d141,
title = "A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET",
abstract = "We undertook this study to estimate the event-free survival (EFS) of patients with newly diagnosed supratento-rial primitive neuroectodermal tumor (SPNET) treated with risk-adapted craniospinal irradiation (CSI) with additional radiation to the primary tumor site and subsequent high-dose chemotherapy supported by stem cell rescue. Between 1996 and 2003, 16 patients with SPNET were enrolled. High-risk (HR) disease was differentiated from average-risk (AR) disease by the presence of residual tumor (M0 and tumor size > 1.5 cm2) or disseminated disease in the neuraxis (M1-M 3). Patients received risk-adapted CSI: those with AR disease received 23.4 Gy; those with HR disease, 36-39.6 Gy. The tumor bed received a total of 55.8 Gy. Subsequently, all patients received four cycles of high-dose cyclophosphamide, cisplatin, and vincristine with stem cell support. The median age at diagnosis was 7.9 years; eight patients were female. Seven patients had pineal PNET. Twelve patients are alive at a median follow-up of 5.4 years. The 5-year EFS and overall survival (OS) estimates for all patients were 68{\%} ± 14{\%} and 73{\%} ± 13{\%}. The 5-year EFS and OS estimates were 75{\%} ± 17{\%} and 88{\%} ± 13{\%}, respectively, for the eight patients with AR disease and 60{\%} ± 19{\%} and 58{\%} ± 19{\%}, respectively, for the eight with HR disease. No deaths were due to toxicity. High-dose cyclophosphamide- based chemotherapy with stem cell support after risk-adapted CSI results in excellent EFS estimates for patients with newly diagnosed AR SPNET. Further, this chemotherapy allows for a reduction in the dose of CSI used to treat AR SPNET without compromising EFS.",
author = "Murali Chintagumpala and Tim Hassall and Shawna Palmer and David Ashley and Dana Wallace and Kimberly Kasow and Merchant, {Thomas E.} and Krasin, {Matthew J.} and Robert Dauser and Frederick Boop and Robert Krance and Shiao Woo and Robyn Cheuk and Ching Lau and Richard Gilbertson and Amar Gajjar",
year = "2009",
month = "2",
day = "1",
doi = "10.1215/15228517-2008-079",
language = "English (US)",
volume = "11",
pages = "33--40",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET

AU - Chintagumpala, Murali

AU - Hassall, Tim

AU - Palmer, Shawna

AU - Ashley, David

AU - Wallace, Dana

AU - Kasow, Kimberly

AU - Merchant, Thomas E.

AU - Krasin, Matthew J.

AU - Dauser, Robert

AU - Boop, Frederick

AU - Krance, Robert

AU - Woo, Shiao

AU - Cheuk, Robyn

AU - Lau, Ching

AU - Gilbertson, Richard

AU - Gajjar, Amar

PY - 2009/2/1

Y1 - 2009/2/1

N2 - We undertook this study to estimate the event-free survival (EFS) of patients with newly diagnosed supratento-rial primitive neuroectodermal tumor (SPNET) treated with risk-adapted craniospinal irradiation (CSI) with additional radiation to the primary tumor site and subsequent high-dose chemotherapy supported by stem cell rescue. Between 1996 and 2003, 16 patients with SPNET were enrolled. High-risk (HR) disease was differentiated from average-risk (AR) disease by the presence of residual tumor (M0 and tumor size > 1.5 cm2) or disseminated disease in the neuraxis (M1-M 3). Patients received risk-adapted CSI: those with AR disease received 23.4 Gy; those with HR disease, 36-39.6 Gy. The tumor bed received a total of 55.8 Gy. Subsequently, all patients received four cycles of high-dose cyclophosphamide, cisplatin, and vincristine with stem cell support. The median age at diagnosis was 7.9 years; eight patients were female. Seven patients had pineal PNET. Twelve patients are alive at a median follow-up of 5.4 years. The 5-year EFS and overall survival (OS) estimates for all patients were 68% ± 14% and 73% ± 13%. The 5-year EFS and OS estimates were 75% ± 17% and 88% ± 13%, respectively, for the eight patients with AR disease and 60% ± 19% and 58% ± 19%, respectively, for the eight with HR disease. No deaths were due to toxicity. High-dose cyclophosphamide- based chemotherapy with stem cell support after risk-adapted CSI results in excellent EFS estimates for patients with newly diagnosed AR SPNET. Further, this chemotherapy allows for a reduction in the dose of CSI used to treat AR SPNET without compromising EFS.

AB - We undertook this study to estimate the event-free survival (EFS) of patients with newly diagnosed supratento-rial primitive neuroectodermal tumor (SPNET) treated with risk-adapted craniospinal irradiation (CSI) with additional radiation to the primary tumor site and subsequent high-dose chemotherapy supported by stem cell rescue. Between 1996 and 2003, 16 patients with SPNET were enrolled. High-risk (HR) disease was differentiated from average-risk (AR) disease by the presence of residual tumor (M0 and tumor size > 1.5 cm2) or disseminated disease in the neuraxis (M1-M 3). Patients received risk-adapted CSI: those with AR disease received 23.4 Gy; those with HR disease, 36-39.6 Gy. The tumor bed received a total of 55.8 Gy. Subsequently, all patients received four cycles of high-dose cyclophosphamide, cisplatin, and vincristine with stem cell support. The median age at diagnosis was 7.9 years; eight patients were female. Seven patients had pineal PNET. Twelve patients are alive at a median follow-up of 5.4 years. The 5-year EFS and overall survival (OS) estimates for all patients were 68% ± 14% and 73% ± 13%. The 5-year EFS and OS estimates were 75% ± 17% and 88% ± 13%, respectively, for the eight patients with AR disease and 60% ± 19% and 58% ± 19%, respectively, for the eight with HR disease. No deaths were due to toxicity. High-dose cyclophosphamide- based chemotherapy with stem cell support after risk-adapted CSI results in excellent EFS estimates for patients with newly diagnosed AR SPNET. Further, this chemotherapy allows for a reduction in the dose of CSI used to treat AR SPNET without compromising EFS.

UR - http://www.scopus.com/inward/record.url?scp=61449248205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449248205&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-079

DO - 10.1215/15228517-2008-079

M3 - Article

C2 - 18796696

AN - SCOPUS:61449248205

VL - 11

SP - 33

EP - 40

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -